Introduction {#H1-1-ZOI190129}
============

Childhood and adolescent cancers constitute a heterogeneous group of rare diseases. Multicentric clinical trials have led to the continuing refinement of cancer subtype classification and the development of improved risk-adapted treatment strategies, with overall survival rates currently reaching approximately 80%.^[@zoi190129r1],[@zoi190129r2]^ Despite these advances, cases of refractory and recurrent cancers are associated with a poor prognosis and death. The hard-to-treat cancers remain the leading cause of disease-related mortality among children and adolescents in Western countries.^[@zoi190129r3],[@zoi190129r4],[@zoi190129r5],[@zoi190129r6]^ Little progress has been made to further improve the outcomes of these patients, highlighting the urgent need for new research avenues to tackle this challenge.

The use of comprehensive molecular profiling in the clinical management of children and adolescents with cancer appears a suitable approach to improve patient care and outcomes, particularly for hard-to-treat cases. The advent of next-generation sequencing (NGS) technologies has revolutionized the study of cancers, offering unprecedented opportunities to fully characterize cancer genomes. It has accelerated the search for somatic mutations, which can now be applied to whole genomes and transcriptomes to unravel molecular signatures.^[@zoi190129r7],[@zoi190129r8],[@zoi190129r9],[@zoi190129r10],[@zoi190129r11],[@zoi190129r12]^ In-depth molecular profiling of individual tumors has allowed the identification of potentially actionable mutations that could lead to therapeutic interventions and new drug targets.^[@zoi190129r11],[@zoi190129r13],[@zoi190129r14],[@zoi190129r15],[@zoi190129r16]^ Several initiatives have begun to integrate cancer genomic--based information into the care of patients with childhood cancer. These initiatives have demonstrated the feasibility of such strategies at a single site or across multiple sites.^[@zoi190129r17],[@zoi190129r18],[@zoi190129r19],[@zoi190129r20],[@zoi190129r21],[@zoi190129r22]^ They have reported many genomic biomarkers or oncogenic drivers that have been proven useful to tailored patient management.

Working toward this goal, we carried out the TRICEPS study, the personalized targeted therapy in refractory or relapsed cancer in childhood study. The TRICEPS study targeted cases of childhood and adolescent cancer from all 4 pediatric medical oncology centers in the province of Québec, Canada. The primary objective was to assess the feasibility of identifying potentially actionable mutations using NGS-based assays in a clinically relevant time frame. In this current study, we report the results from a cohort of 84 consecutive and clinically well-characterized patients enrolled in the TRICEPS study who underwent extensive molecular profiling. The multimodal genomic and transcriptomic strategies effectively identified various types of genomic alterations, including expressed gene fusions, single-nucleotide variants (SNVs), small insertions/deletions (indels), and copy number alterations (CNAs), that improved the detection of potentially actionable alterations of clinical relevance.

Methods {#H1-2-ZOI190129}
=======

Study Design and Participants {#H2-1-ZOI190129}
-----------------------------

The TRICEPS study, a prospective multimodal genome sequencing study, launched in April 2014 at a single institution, the Centre Hospitalier Universitaire Sainte-Justine in Montreal, Québec, Canada. After a feasibility phase of 2 years (involving patients 1 to 30), the TRICEPS study enrolled patients through January 2018 from all 4 pediatric oncology centers in the province of Québec (Centre Hospitalier Universitaire Sainte-Justine, McGill University Health Centre, Centre Hospitalier Universitaire de Québec--Université Laval, and Centre Hospitalier Universitaire de Sherbrooke). This study was approved by the Research Ethics Board of Centre Hospitalier Universitaire Sainte-Justine. Approved informed consent forms were provided to and completed by all patients. Details of patient enrollment are available in eMethods in the [Supplement](#note-ZOI190129-1-s){ref-type="supplementary-material"}. This study followed the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis ([TRIPOD](http://www.equator-network.org/reporting-guidelines/tripod-statement/)) reporting guideline.

Molecular Profiling and Data Analysis {#H2-2-ZOI190129}
-------------------------------------

### Whole-Exome Sequencing and RNA Sequencing {#H3-1-ZOI190129}

Whole exomes were captured in solution using a kit (SureSelect XT Clinical Research Exome; Agilent) and according to the manufacturer\'s instructions. Paired-end sequencing (2 × 75 base pairs \[bp\]) of matched normal and tumor materials was performed on the sequencing system (HiSeq 2500 or HiSeq 4000; Illumina) at the Integrated Centre for Pediatric Clinical Genomics of the Centre Hospitalier Universitaire Sainte-Justine, with an expected mean coverage on targeted region of 300X for tumor and 100X for germline sequences. This coverage allowed the detection of subclonal populations present at 10% or more in tumor material (D.S.; unpublished data; May 2012). To be more time efficient, we performed a first sequence variant analysis on data from a virtual 979 cancer genes panel (eTable 1 in the [Supplement](#note-ZOI190129-1-s){ref-type="supplementary-material"}). This panel was built from a compilation of genes present in the COSMIC (Catalogue of Somatic Mutations in Cancer) database,^[@zoi190129r23]^ FoundationOne Heme genomic profiling test,^[@zoi190129r40]^ and My Cancer Genome precision cancer medicine tool.^[@zoi190129r41]^ Bioinformatics analysis was performed as described elsewhere.^[@zoi190129r24]^ Details of pipelines used for this analysis are given in eFigure 1 and eMethods in the [Supplement](#note-ZOI190129-1-s){ref-type="supplementary-material"}.

RNA libraries (TruSeq Stranded Total RNA Library Prep Kit; Illumina) were prepared from cancer cells using a kit (Ribo-Zero Gold kit; Illumina) and according to the manufacturer\'s protocol. The resulting libraries (stranded and ribosomal RNA depleted) were sequenced (approximately 150 million reads, paired-end 2 × 75 bp) on a sequencing system (either HiSeq 2500 or HiSeq 4000) at the Integrated Centre for Pediatric Clinical Genomics. Details of the bioinformatics analysis performed and the annotation of genomic alterations are available in eMethods in the [Supplement](#note-ZOI190129-1-s){ref-type="supplementary-material"}.

Potentially Actionable Alteration Categories and Multidisciplinary Molecular Tumor Board {#H2-3-ZOI190129}
----------------------------------------------------------------------------------------

Further annotation was done using published associations with drug or variant sensitivity profiles (eMethods in the [Supplement](#note-ZOI190129-1-s){ref-type="supplementary-material"}). Scientific literature was mined to determine if a given alteration was a target of an approved drug or a target of a drug in clinical development, or if it conferred resistance to known treatments. Then, the somatic alterations were ranked with level of evidence (eFigure 2 in the [Supplement](#note-ZOI190129-1-s){ref-type="supplementary-material"}). This information was integrated to identify potentially actionable alterations, grouped in 1 of 4 categories: targeted therapy, minimal residual disease/biomarker, risk stratification, and diagnostic (eMethods in the [Supplement](#note-ZOI190129-1-s){ref-type="supplementary-material"}).

The patient's specific molecular profile was then reviewed by the TRICEPS study's multidisciplinary molecular tumor board (MMTB), which included experts in pediatric oncology, genomics, bioinformatics, medical genetics, surgery, and pathology. Any treatment decision based on the molecular profiling that outlined potentially actionable alterations or the decision to prescreen patients for ongoing clinical trials was made entirely by the treating team and the patients and their family.

Results {#H1-3-ZOI190129}
=======

Patient Characteristics and Samples {#H2-4-ZOI190129}
-----------------------------------

A total of 85 consecutive patients with relapsed or refractory or hard-to-treat cancer were eligible, and only 1 patient declined participation. Thus, 84 children and adolescents with various types of cancer diagnosis ([Figure 1](#zoi190129f1){ref-type="fig"} and the [Table](#zoi190129t1){ref-type="table"}) were enrolled in the TRICEPS study. The sample had a mean (range) age of 10.1 (1-21) years and a similar proportion of male (45 \[54%\]) and female (39 \[46%\]).

![Enrollment Overview and Distribution of Potentially Actionable Alterations\
[MRD]{.smallcaps} indicates minimal residual disease.](jamanetwopen-2-e192906-g001){#zoi190129f1}

###### Summary of the Molecular Profiling of 62 Patients

  Patient No.                                                                                                                                                                  Cancer Type                                  Tissue Type and Source                        Mean Coverage, X   RNA, Million Reads   Potentially Actionable Somatic Alteration   Potentially Actionable Germline Alteration                                                                                                   Category of Potentially Actionable Findings   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------- --------------------------------------------- ------------------ -------------------- ------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------- ------------------------------------------------------
  2                                                                                                                                                                            ETP-ALL                                      Bone marrow                                   61                 76                   98                                          *MLLT10-PICALM* fusion; *KMT2E-ASNS* fusion                                                                                                  NA                                            Targeted therapy, MRD/biomarker, diagnostic
  del(5q)                                                                                                                                                                      NA                                           Targeted therapy                                                                                                                                                                                                                                                                                                             
  5                                                                                                                                                                            Ewing sarcoma                                Left femur biopsy                             257                233                  NA                                          ERCC2 F332V                                                                                                                                  NA                                            No effect
                                                                                                                                                                               SDHD G12S                                    Genetic counseling                                                                                                                                                                                                                                                                                                           
  10                                                                                                                                                                           Rhabdomyosarcoma                             Thigh biopsy                                  196                194                  NA                                          *PAX7-FOXO1* fusion                                                                                                                          NA                                            MRD/biomarker, diagnostic
  *MDM2* amplification; CDKN2A A102V                                                                                                                                           NA                                           Targeted therapy                                                                                                                                                                                                                                                                                                             
  11                                                                                                                                                                           Pilocytic astrocytoma                        CNS needle biopsy                             191                289                  NA                                          BRAF 507insVLR                                                                                                                               NA                                            Targeted therapy
  12                                                                                                                                                                           Malignant rhabdoid tumor                     Intra-abdominal biopsy                        124                455                  947                                         No potentially actionable findings                                                                                                           NA                                            No effect
  13                                                                                                                                                                           Medulloblastoma                              Cerebellum biopsy                             128                383                  75                                          PTCH1 T1195S and *PTCH1* copy loss (LOH), *GLI2* amplification                                                                               NA                                            Targeted therapy
  TP53K132N and *TP53* copy loss (LOH)                                                                                                                                                                                      No effect                                                                                                                                                                                                                                                                                                                    
  14                                                                                                                                                                           AML-M7                                       Bone marrow                                   88                 507                  115                                         *NUP98-KDM5A* fusion                                                                                                                         NA                                            MRD/biomarker
  *RB1* copy loss                                                                                                                                                              NA                                           No effect                                                                                                                                                                                                                                                                                                                    
  15                                                                                                                                                                           B-ALL                                        Bone marrow                                   120                424                  362                                         *CDKN2A/B* homozygous deletion                                                                                                               NA                                            Targeted therapy
  *DDX5-KLF2* fusion                                                                                                                                                           NA                                           MRD/biomarker                                                                                                                                                                                                                                                                                                                
  TP53 R248Q and *TP53* copy loss (LOH)                                                                                                                                        NA                                           No effect                                                                                                                                                                                                                                                                                                                    
  19                                                                                                                                                                           B-ALL                                        Bone marrow (diagnosis)                       115                355                  172                                         *PAX5-JAK2* fusion                                                                                                                           NA                                            Targeted therapy, MRD/biomarker, risk stratification
  *CDKN2A* homozygous deletion                                                                                                                                                 NA                                           Targeted therapy                                                                                                                                                                                                                                                                                                             
  PAX5 A322T and *PAX5* copy loss (LOH)                                                                                                                                        NA                                           No effect                                                                                                                                                                                                                                                                                                                    
  20                                                                                                                                                                           Adrenal gland carcinoma                      Adrenal gland biopsy                          98                 248                  178                                         *AKT1* amplification (4 copies)                                                                                                              NA                                            Targeted therapy
  *JAK1* copy gain                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  DPYD I543V and *DPYD* copy loss (LOH)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  TP53 R181H and *TP53* copy loss (LOH)                                                                                                                                        NA                                           No effect                                                                                                                                                                                                                                                                                                                    
  21                                                                                                                                                                           Osteosarcoma                                 Left femur biopsy                             105                282                  168                                         *MDM2* (6 copies) and *FRS2* (12 copies) amplifications, *AURKA* copy gain                                                                   NA                                            Targeted therapy
  *PMP22-TP53* fusion                                                                                                                                                          NA                                           MRD/biomarker                                                                                                                                                                                                                                                                                                                
  22                                                                                                                                                                           ETP-ALL                                      Bone marrow                                   88                 265                  131                                         JAK3 L857P, PHF6 R225X, MED12 S672fs                                                                                                         NA                                            Targeted therapy
  *KMT2E-ASNS* fusion                                                                                                                                                          NA                                           Targeted therapy, MRD/biomarker                                                                                                                                                                                                                                                                                              
  *PICALM-MLLT10* fusion                                                                                                                                                       NA                                           Targeted therapy, MRD/biomarker, diagnostic                                                                                                                                                                                                                                                                                  
  24                                                                                                                                                                           B-ALL                                        Bone marrow                                   107                406                  137                                         BRAF A320V, KRAS G12V, JAK2 R683G                                                                                                            NA                                            Targeted therapy
  25                                                                                                                                                                           Hepatoblastoma                               Liver biopsy (FFPE sample)                    72                 230                  122                                         *PRKCA* copy gain, ABL2 and *DDR2* copy gain and high expression, NOTCH1 G1196D, NCSTN A572G, TLR8 N515H                                     NA                                            Targeted therapy
  26                                                                                                                                                                           Osteosarcoma                                 Right femur biopsy                            145                390                  66                                          *MYC* amplification (5 copies)                                                                                                               NA                                            Targeted therapy
  *TP53* copy loss, *RB1* copy loss                                                                                                                                            NA                                           No effect                                                                                                                                                                                                                                                                                                                    
  29                                                                                                                                                                           Adrenal gland carcinoma                      Adrenal gland biopsy                          87                 261                  164                                         *PTK2* copy gain, *JAK3* copy gain, AKT2 copy gain, ABL1 A34V, TOP2A A1515S, G1386D (LOH)                                                    NA                                            Targeted therapy
  NA                                                                                                                                                                           TP53p. R337H                                 Diagnostic, genetic counseling                                                                                                                                                                                                                                                                                               
  31                                                                                                                                                                           Neuroblastoma                                Mediastinum biopsy                            100                226                  102                                         Trisomy 7 (*BRAF*), *CHEK1* copy loss, *PRKCA* copy gain, PHOX2B 270-272del frameshift, XPC S346P (LOH), APC D917Y                           NA                                            Targeted therapy
  32                                                                                                                                                                           AML-M5                                       Bone marrow                                   90                 252                  149                                         *CBFB-MYH11* and *ICAM2-STX7* fusion                                                                                                         NA                                            MRD/biomarker
  *TP53* (indel) mutation and copy loss (LOH)                                                                                                                                  NA                                           No effect                                                                                                                                                                                                                                                                                                                    
  Trisomy 8 (*MYC*), NF1 S2309fs and *NF1* copy loss (LOH)                                                                                                                     NA                                           Targeted therapy                                                                                                                                                                                                                                                                                                             
  33                                                                                                                                                                           Paraganglioma                                Adrenal gland biopsy                          111                308                  134                                         SD*HB* copy loss, DDB2 copy loss, MUTYH Q338H                                                                                                NA                                            Targeted therapy
  34                                                                                                                                                                           Aggressive fibromatosis                      Mandible/gums biopsy                          60                 178                  193                                         CTNNB1 T41A                                                                                                                                  NA                                            Targeted therapy
  37                                                                                                                                                                           B-ALL                                        Bone marrow                                   70                 206                  131                                         *KMT2A-MLLT1* fusion                                                                                                                         NA                                            MRD/biomarker
  39                                                                                                                                                                           Ewing sarcoma                                Rib needle biopsy                             138                372                  254                                         *CDKN2A* copy loss, trisomy 8 (*MYC* and *FGFR1*), BRCA1 mutations (LOH), STAG2 R1012X                                                       NA                                            Targeted therapy
  TP53 R273H                                                                                                                                                                   NA                                           No effect                                                                                                                                                                                                                                                                                                                    
  *EWSR1/FLI1* fusion                                                                                                                                                          NA                                           MRD/biomarker, diagnostic                                                                                                                                                                                                                                                                                                    
  NA                                                                                                                                                                           SDHD G12S                                    Genetic counseling                                                                                                                                                                                                                                                                                                           
  40                                                                                                                                                                           Wilms tumor                                  Kidney needle biopsy                          122                381                  238                                         *DDR2* and ABL2 copy gain, DNMT3A P904L                                                                                                      NA                                            Targeted therapy
  47                                                                                                                                                                           T-ALL                                        Bone marrow                                   90                 256                  133                                         *CDKN2A* homozygous deletion, NOTCH1 I1718T and S2467fs, STAT5B N642H, NT5C2 R367Q                                                           NA                                            Targeted therapy
  48                                                                                                                                                                           Myeloproliferative neoplasm                  Bone marrow                                   75                 179                  132                                         No findings                                                                                                                                  NA                                            No effect
  49                                                                                                                                                                           Rhabdomyosarcoma                             Left fornix biopsy                            100                252                  127                                         FGFR4 G388R (LOH)                                                                                                                            NA                                            Targeted therapy
  *TP53* copy loss (LOH)                                                                                                                                                       TP53 p.R273C                                 Diagnostic, genetic counseling                                                                                                                                                                                                                                                                                               
  50                                                                                                                                                                           Pilocytic astrocytoma                        Brain, third ventricle biopsy                 73                 380                  217                                         FGFR1 656EL, NF1 N1465S, PTPN11 G503A                                                                                                        NA                                            Targeted therapy
  51                                                                                                                                                                           Osteosarcoma                                 Left femur biopsy                             134                411                  202                                         *TP53* copy loss (LOH)                                                                                                                       TP53 p.G245S (mosaicism)                      Genetic counseling
  *CDKN2A* homozygous deletion, *VEGF-A* amplification (\>4 copies), *MYC* amplification (\>10 copies), JAK2 G996R, CSF1R H362R (LOH), PTK2 exon17:c.1332 + 2T\>C (splicing)   NA                                           Targeted therapy                                                                                                                                                                                                                                                                                                             
  54                                                                                                                                                                           Pilocytic astrocytoma                        Optic chiasm--hypothalamus biopsy             142                383                  183                                         *KIAA1549-BRAF* fusion                                                                                                                       NA                                            Targeted therapy, MRD/biomarker
  55                                                                                                                                                                           Osteosarcoma                                 Right tibia biopsy                            89                 285                  112                                         TEK N452D, KIT S590I, *MYC* amplification (10 copies)                                                                                        NA                                            Targeted therapy
  *TP53* homozygous del                                                                                                                                                        NA                                           No effect                                                                                                                                                                                                                                                                                                                    
  57                                                                                                                                                                           Neuroblastoma                                Abdomen biopsy                                125                419                  54                                          *PRKCA* amplification (5 copies), *BRAF* amplification (4 copies), *AKT2* copy gain, HSP90B1 I66T, CSF1R N648S                               NA                                            Targeted therapy
  59                                                                                                                                                                           Osteosarcoma                                 Left femur biopsy                             135                408                  202                                         *VEGF-A* amplification (4 copies) and highly expressed                                                                                       NA                                            Targeted therapy
  *TP53-RAB44* fusion                                                                                                                                                          NA                                           MRD/biomarker                                                                                                                                                                                                                                                                                                                
  60                                                                                                                                                                           T-Cell lymphoblastic lymphoma                Lymph node                                    135                404                  157                                         MAP2K2 P128L, NOTCH1 S1674F and Q2503insX, MTOR F1888L, CDKN2A R80X, STAT5B N713insKGKGGG                                                    NA                                            Targeted therapy
  *KLHL33-TEP1* fusion                                                                                                                                                         NA                                           MRD/biomarker                                                                                                                                                                                                                                                                                                                
  61                                                                                                                                                                           Osteosarcoma                                 Left humerus biopsy                           128                453                  178                                         *CDKN2A* copy loss, *MYC* copy gain, DDR2 copy gain and highly expressed, MTOR G1954R                                                        NA                                            Targeted therapy
  62                                                                                                                                                                           Sinus carcinoma                              Sinus biopsy                                  111                289                  163                                         *PTK2* copy gain, *MYC* copy gain, *ABL2* and DDR2 copy gain, ALK G159fs, NOTCH1 S1674P                                                      NA                                            Targeted therapy
  *TP53* copy loss                                                                                                                                                             NA                                           No effect                                                                                                                                                                                                                                                                                                                    
  67                                                                                                                                                                           Epithelial tumor (NOS)                       Abdomen biopsy                                138                430                  51                                          *CREM-FUS* fusion                                                                                                                            NA                                            MRD/biomarker
  68                                                                                                                                                                           T-ALL                                        Bone marrow                                   59                 203                  65                                          ABL1 copy gain, DDR2 R742W                                                                                                                   NA                                            Targeted therapy
  *KMT2A-MLLT4* fusion                                                                                                                                                         NA                                           Targeted therapy, MRD/biomarker                                                                                                                                                                                                                                                                                              
  69                                                                                                                                                                           Grey zone lymphoma                           Lymph node                                    64                 246                  70                                          NA                                                                                                                                           TP53 p.R213Q                                  Diagnostic, genetic counseling
  70                                                                                                                                                                           Leiomyoma                                    Clavicle biopsy                               67                 236                  55                                          No potentially actionable findings                                                                                                           NA                                            No effect
  71                                                                                                                                                                           Hepatoblastoma                               Liver biopsy                                  62                 237                  64                                          No findings                                                                                                                                  NA                                            No effect
  72                                                                                                                                                                           Hepatocarcinoma                              Liver biopsy                                  119                346                  120                                         *DNAJB1-PRKACA* fusion                                                                                                                       NA                                            MRD/biomarker, diagnostic
  73                                                                                                                                                                           Pleuropulmonary blastoma                     Right lung biopsy                             113                311                  92                                          *MYC* and *FGFR1* copy gain and highly expressed, *CHEK1* copy loss, CTNNB1 copy gain and very highly expressed, MET Q1276L, DICER1 E1813D   NA                                            Targeted therapy
  NA                                                                                                                                                                           DICER p.Y1225X                               Diagnostic, genetic counseling                                                                                                                                                                                                                                                                                               
  74                                                                                                                                                                           NUT-midline carcinoma                        Left fibula needle biopsy                     115                354                  149                                         *BRD4-NUTM1* fusion                                                                                                                          NA                                            MRD/biomarker, diagnostic
  76                                                                                                                                                                           Neuroblastoma                                Abdominal needle biopsy                       103                318                  109                                         *CDKN2A* homozygous deletion, *MET* amplification (4 copies) and highly expressed, *PHOX2B* copy loss, CHEK1 copy loss, ALK F1245I           NA                                            Targeted therapy
  77                                                                                                                                                                           Round cell sarcoma                           Soft-tissue left ankle biopsy                 109                272                  67                                          *BCOR*exon16 ITD, *DDR2* copy gain                                                                                                           NA                                            Diagnostic, targeted therapy
  78                                                                                                                                                                           Rhabdomyosarcoma                             Right calf biopsy                             113                393                  147                                         *MYCN* amplification (5 copies) and highly expressed, KDM1A G703R (LOH)                                                                      NA                                            Targeted therapy
  *PAX7-FOXO1* fusion                                                                                                                                                          NA                                           MRD/biomarker, diagnostic                                                                                                                                                                                                                                                                                                    
  79                                                                                                                                                                           Osteosarcoma                                 Left tibia biopsy (FFPE)                      121                367                  190                                         SMO A374E, FBXW7 R465H                                                                                                                       NA                                            Targeted therapy
  81                                                                                                                                                                           B-ALL                                        Bone marrow                                   123                298                  143                                         NRAS G12D, SETD2 E1265fs                                                                                                                     NA                                            Targeted therapy
  82                                                                                                                                                                           B-ALL                                        Bone marrow                                   113                311                  215                                         *IKZF1* deletion, FLT3 Y589D                                                                                                                 NA                                            Targeted therapy
  *ZEB2-CXCR4* fusion and *CXCR4* very highly expressed, SEM*A6A-FEM1C* fusion                                                                                                 NA                                           MRD/biomarker                                                                                                                                                                                                                                                                                                                
  86                                                                                                                                                                           Metastatic Wilms tumor                       Right kidney biopsy                           106                287                  143                                         CDC73 M1V, CSF3R G751A, FLT4 A992fs, NTRK1 G607V and H598Y and copy loss (LOH)                                                               NA                                            Targeted therapy
  87                                                                                                                                                                           Gastric NET                                  Celiac lymph node biopsy                      99                 256                  38                                          *CHEK1* copy loss                                                                                                                            NA                                            No effect
  88                                                                                                                                                                           Burkitt lymphoma                             Abdomen biopsy                                115                364                  38                                          B2M M1R, HDAC1 Y303H, *PIK3C2A* splicing mutation, CCND3 R256fs, *PTEN* copy loss                                                            NA                                            Targeted therapy
  *IGH-MYC* fusion                                                                                                                                                             NA                                           MRD/biomarker                                                                                                                                                                                                                                                                                                                
  TP53 G302fs                                                                                                                                                                  NA                                           No effect                                                                                                                                                                                                                                                                                                                    
  89                                                                                                                                                                           B-ALL                                        Bone marrow                                   56                 134                  111                                         *CDKN2A* homozygous deletion, AURKA copy loss, NRAS G12D                                                                                     NA                                            Targeted therapy
  91                                                                                                                                                                           Teratoma malignant (NOS)                     Brain, left ventricle biopsy                  103                261                  107                                         No findings                                                                                                                                  NA                                            No effect
  92                                                                                                                                                                           AML                                          Bone marrow                                   61                 179                  134                                         NRAS G12D                                                                                                                                    NA                                            Targeted therapy
  *KMT2A-MLLT3* fusion                                                                                                                                                         NA                                           MRD/biomarker                                                                                                                                                                                                                                                                                                                
  93                                                                                                                                                                           Ganglioneuroblastoma nodular                 Retroperitoneal biopsy                        142                340                  80                                          MET K324M, High *ALK* expression                                                                                                             NA                                            Targeted therapy
  94                                                                                                                                                                           Lymphoma                                     Mediastinum biopsy (FFPE)                     66                 246                  NA                                          *CDKN2A* homozygous deletion,                                                                                                                NA                                            Targeted therapy
  PTEN L182fs and copy-neutral LOH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  99                                                                                                                                                                           AML                                          Bone marrow                                   76                 248                  109                                         HDAC2 E455fs                                                                                                                                 NA                                            Targeted therapy
  *KHDRBS3-ANGPT1* fusion                                                                                                                                                                                                   Targeted therapy, MRD/biomarker                                                                                                                                                                                                                                                                                              
  100                                                                                                                                                                          Ovarian tumor                                Ovary biopsy                                  82                 268                  72                                          CD74 P98S                                                                                                                                    NA                                            Targeted therapy
  102                                                                                                                                                                          Melanotic neuroectodermal tumor of infancy   Periostium skull lesion biopsy (FFPE)         83                 170                  NA                                          No potentially actionable findings                                                                                                           NA                                            No effect
  104                                                                                                                                                                          Alveolar rhabdomyosarcoma                    Right foot biopsy                             359                160                  77                                          *PAX3-FOXO1* fusion                                                                                                                          NA                                            MRD/biomarker, diagnostic
  RB1 F650S and copy loss (LOH)                                                                                                                                                NA                                           No effect                                                                                                                                                                                                                                                                                                                    
  106                                                                                                                                                                          Neuroblastoma                                Right adrenal biopsy                          131                352                  64                                          *MYCN* amplification (10 copies)                                                                                                             NA                                            Targeted therapy
  SDHB S163P                                                                                                                                                                   Genetic counseling                                                                                                                                                                                                                                                                                                                                                        

Abbreviations[:]{.smallcaps} AML, acute myeloid leukemia; B-ALL, B-cell acute lymphoblastic leukemia; CNS, central nervous system; ETP-ALL, early T-cell precursor acute lymphoblastic leukemia; FFPE, formalin-fixed, paraffin embedded; [LOH,]{.smallcaps} loss of heterozygosity; [MRD,]{.smallcaps} minimal residual disease; NA, not applicable; NET, neuroendocrine tumors; NOS, not otherwise specified; NUT, nuclear protein of the testis; T-ALL, T-cell acute lymphoblastic leukemia; VEGF-A, vascular endothelial growth factor A; WES, whole-exome sequencing.

Tissues were suitable for molecular profiling in 62 of 84 eligible patients (74%). The mutations in 62 patients were drug-targetable alterations (47 \[76%\]), alterations that modify diagnosis or risk stratification (13 \[21%\]), or alterations with a potential for disease monitoring (23 \[37%\]). For patient 19 (pre--B-cell acute lymphoblastic leukemia), we sequenced the primary leukemia sample because of low blast count (≤25%) in the relapsed sample; then, we confirmed the results in the relapsed material. Five solid tumor samples (patients 5, 10, 11, 94, and 102) were not subjected to transcriptomic analysis because of poor RNA quality (RNA integrity number values \<5) or not enough RNA. The remaining 22 patients (26%) were considered as screening failure, owing to benign or necrotic biopsies (n = 7), low tumor content (≤25% tumor purity; n = 14), or insufficient material (n = 1), resulting in suboptimal DNA/RNA quantity or quality suitable for NGS ([Figure 1](#zoi190129f1){ref-type="fig"}).

Overall Genomic Alterations Detected by Whole-Exome Sequencing and RNA Sequencing {#H2-5-ZOI190129}
---------------------------------------------------------------------------------

For whole-exome sequencing (WES), the median (range) coverage depth was 294X (76X-506X) for the tumoral exomes and 106X (54X-256X) for the normal exomes (the summary of sequencing depth is presented in the [Table](#zoi190129t1){ref-type="table"}). The analysis of a virtual 979 cancer gene panel (eTable 1 in the [Supplement](#note-ZOI190129-1-s){ref-type="supplementary-material"}) from the WES data was prioritized to identify somatic genetic changes in tumors (the molecular profiling findings are summarized in [Figure 1](#zoi190129f1){ref-type="fig"} and the [Table](#zoi190129t1){ref-type="table"}).

The comprehensive genomic analysis detected at least 1 potentially actionable alteration in 54 of 62 patients (87%) ([Figure 1](#zoi190129f1){ref-type="fig"}). Among these alterations (n = 191), missense mutations were the most frequent (73 \[38%\]), whereas mutations that resulted in indels, prematurely truncated proteins, or splicing site changes made up most (15 \[8%\]) of the remaining alterations ([Table](#zoi190129t1){ref-type="table"}). All potentially actionable alterations were verified through orthogonal methods (MiSeq sequencing, quantitative polymerase chain reaction \[PCR\], or reverse-transcriptase PCR). The tumor mutation burden (TMB), a measurement of the overall number of mutations carried by tumor cells, assessed from WES data ([Figure 2](#zoi190129f2){ref-type="fig"}) ranged from 1 or lower to 8 with a mean (SD) of 1.87 (1.87) and a median of 1.09. Approximately 10% of patients (6 of 59) had a TMB higher than 5, which may gauge a response to immunotherapy agents.^[@zoi190129r26]^ Copy number alterations were found in 12 genomic regions containing genes present in the virtual 979 cancer gene panel (eTable 1 in the [Supplement](#note-ZOI190129-1-s){ref-type="supplementary-material"}). Quantitative PCR validation indicated that detection of CNAs was highly concordant with results obtained using standard techniques, including fluorescence in situ hybridization. These results demonstrate the power of the WES-based assay to detect cancer-associated CNAs. Using the germline WES data, we identified 8 (13%) of 62 patients carrying 1 germline pathogenic variant in the virtual cancer predisposition gene (eTable 2 in the [Supplement](#note-ZOI190129-1-s){ref-type="supplementary-material"}).

![Tumor Mutation Burden for 62 Patients\
Distribution of the somatic tumor mutation burden is defined as the number of nonsynonymous coding mutations per megabase. Each bar indicates the mutation number in each sample. The blue line indicates the median of the TMB in the cohort (1.09), and the orange line indicates pediatric high threshold, as determined by Gröbner et al.^[@zoi190129r25]^ Solid tumors are labeled in tan, brain tumors in orange, and hematological malignant neoplasms in blue.\
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; ETP, early T-cell precursor; NET, neuroendocrine tumors; NUT, nuclear protein of the testis.](jamanetwopen-2-e192906-g002){#zoi190129f2}

For RNA sequencing (or whole-transcriptome sequencing), the mean (range) coverage depth was 140 million (38.4 million-362 million) reads. Using this data set, we detected at least 1 expressed gene fusion in 23 of the 57 patients (40%) tested, mostly in leukemias (12 of 18) and sarcomas (6 of 13) ([Table](#zoi190129t1){ref-type="table"}). RNA sequencing was also used to validate the presence of 93% of the SNVs (n = 88) and all estimated splicing mutations (n = 2) found within WES data. Thus, RNA sequencing can be used as orthogonal validation of expressed WES data.

Clinical Relevance of the Potential Actionable Alterations {#H2-6-ZOI190129}
----------------------------------------------------------

The median (range) time frame from patient enrollment to MMTB meeting was 8.76 (4.6-17.1) weeks, including 24 (4-41) calendar days from NGS to data annotation. At least 1 potentially actionable alteration was found in 54 of 62 patients (87%) ([Figure 1](#zoi190129f1){ref-type="fig"} and [Table](#zoi190129t1){ref-type="table"}). These alterations might either have changed the initial diagnosis (for 12 of 54 patients \[22%\]) or refined the risk stratification (for 1 of 54 patients \[2%\]) ([Figure 1](#zoi190129f1){ref-type="fig"}). In 23 patients (43%), we found at least 1 expressed gene fusion that could be used to detect and follow minimal residual disease (MRD). In 47 of 54 patients (87%), we found at least 1 mutation (or associated pathways) that could be targeted by a US Food and Drug Administration--approved drug or a drug in clinical trial. Nine of these 47 patients (19%) received a targeted therapy according to the molecular profile. For 2 additional patients, the targeted therapy based on the alterations detected was already part of the treatment received ([Box](#zoi190129b1){ref-type="boxed-text"}). In addition, 18 of the 54 patients (33%) were on a second or third line of treatment, were in remission, or had stable disease at the moment of the report delivery. They were classified as standby as no action had been taken yet ([Figure 1](#zoi190129f1){ref-type="fig"}). Furthermore, 5 of the 62 patients (8%) analyzed died before the end of the process.

###### Summary of Actions Taken Based on Detected Potentially Actionable Alterations by Patient Identification Number and Tumor Type

1.  **2 ETP-ALL:** Patient has been reclassified as an ETP-ALL. RT-PCR assay was designed for *MLLT10-PICALM* fusion MRD follow-up.

2.  **14 AML-M7:** RT-PCR assay was designed for *NUP98-KDM5A* fusion MRD follow-up.

3.  **15 B-ALL:** RT-PCR assay was designed for *DDX5-KLF2* fusion MRD follow-up. Proposed immunotherapy according to *TP53* mutation and LOH.

4.  **19 B-ALL:** RT-PCR assay was designed for *PAX5-JAK2* fusion MRD follow-up. The patient was reclassified as having a Ph-like ALL (very high risk). Ruxolitinib phosphate given to avoid GVHD.

5.  **20 Adrenal gland carcinoma:** Chromosomal instability in the tumor and *TP53* R181H and LOH; referring physician suggested complete surgery.

6.  **22 ETP-ALL:** The patient was reclassified as an ETP-ALL, and the treatment plan has changed consequently. *PICALM-MLLT10* was used for MRD follow-up.

7.  **24 B-ALL:** Ruxolitinib has been used to avoid GVHD for 1 month according to *JAK2* mutation, and then stopped because of encephalopathy. Sirolimus was also used to avoid GVHD.

8.  **25 Hepatoblastoma:** Dasatinib was given as a single agent based on *DDR2* gain and high expression.

9.  **32 AML-M5:** Sirolimus was used to avoid GVHD according to *NF1* mutation and LOH.

10. **34 Aggressive fibromatosis:** Patient was already receiving celecoxib.

11. **39 Ewing Sarcoma:** The patient was referred to the medical genetics division for familial investigation according to *TP53* mutation.

12. **47 T-ALL:** Nelarabine and dasatinib have been added to treatment for the third induction according to *NT5C2* and *STAT5B* mutations.

13. **49 Rhabdomyosarcoma:** The patient received pazopanib hydrochloride in monotherapy according to the *FGFR* mutation.

14. **50 Pilocytic astrocytoma:** The patient is receiving trametinib dimethyl sulfoxide based on *NF1* mutation and shows partial response after 8 months.

15. **54 Pilocytic astrocytoma:** The patient was already on a clinical trial for MEK inhibitor according to the *KIAA1549-BRAF* fusion detected in clinic.

16. **57 Neuroblastoma:** Dabrafenib mesylate was proposed off study to the family. Private insurance would have covered the cost, but parents decided not to go with the treatment.

17. **59 Osteosarcoma:** Pazopanib was started as monotherapy according to *VEGF* expression but was stopped for adverse effects.

18. **69 Grey zone lymphoma:** The patient was referred to the medical genetics division for familial investigation according to *TP53* mutation.

19. **73 Pleuropulmonary blastoma:** Celecoxib was added to therapy according to *CTNNB1* very high expression. Sorafenib was started for progression according to *FGFR1* high expression.

20. **74 NUT-midline carcinoma:** Diagnosis was changed to NUT-midline carcinoma following *BRD4-NUTM1* fusion identification.

21. **77 Round cell sarcoma:** Confirmation of the diagnosis of a rare subtype of round cell sarcoma of infancy that is not responsive to chemotherapy. Complete resection was achieved.

22. **82 B-ALL:** *CXCR4* high expression used for MRD.

[^1]

The alterations in the targeted therapy category were mostly identified by the WES, whereas the MRD/biomarker and risk stratification categories were identified by RNA sequencing, illustrating the power of a multimodal strategy. Of the 12 alterations used for diagnostic, 8 (67%) were detected within the molecular clinical laboratory analysis, particularly fusion products in solid tumor and germline mutations, whereas most of the druggable alterations were detected only by molecular profiling.

The alterations identified in this study were not exclusive, as illustrated by patients carrying several mutations in their cancer ([Table](#zoi190129t1){ref-type="table"}). Some genes or pathways were frequently altered ([Figure 3](#zoi190129f3){ref-type="fig"} and [Figure 4](#zoi190129f4){ref-type="fig"}; eFigure 3 in the [Supplement](#note-ZOI190129-1-s){ref-type="supplementary-material"}). For example, tumor suppressors such as *TP53* (7157) and *CDKN2A* (1029) were altered in 19 (31%) of 62 patients analyzed. Oncogenic kinases were altered in 23 of 62 patients (37%). Two sarcomas (patients 10 and 21) had an *MDM2* (4193) amplification (≥6-fold) that could be targeted by *MDM2* inhibitors.^[@zoi190129r27],[@zoi190129r28]^ The *JAK1/2* (3716) signaling pathway was altered in 6 patients (patients 19, 20, 22, 24, 29, and 51) who could have been treated with *JAK1/2* inhibitors. Some of the fusion gene products putatively participated in key pathways, such as MAPK pathway (patients 2, 22, 54, and 68), *TP53* (patients 21 and 59), and AKT/mTor pathway (patients 29 and 106).

![Summary of the Molecular Profiling of Patients in Oncogene Gene Category\
Data were derived from all 62 patients with completed whole-exome sequencing as well as RNA sequencing of tumors and whole-exome sequencing of germline DNA. The presence of specific mutations, insertion/deletions (indels), amplification/deletions, and genes fusions are indicated by colored circles for hematological malignant neoplasms and solid tumors. Only sequencing findings with biological significance are included. Somatic type included somatic single-nucleotide variants or indels. Sarcoma included rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, round cell sarcoma. Brain type included pilocytic astrocytoma medulloblastoma. Other types included malignant rhaboid tumor, adrenal gland carcinoma, hepatoblastoma, paraganglioma, Wilms tumor, sinus carcinoma, hepatocarcinoma, pleuropulmonary blastoma, NUT midline carcinoma, epithelial tumor, and gastric NET. ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; LOH, loss of heterozygosity; NB, neuroblastoma; NET, neuroendocrine tumors; NUT, nuclear protein of the testis.](jamanetwopen-2-e192906-g003){#zoi190129f3}

![Summary of the Molecular Profiling of Patients in Fusion, Other, and Tumor Suppression Gene Category\
Data were derived from all 62 patients with completed whole-exome sequencing as well as RNA sequencing of tumors and whole-exome sequencing of germline DNA. The presence of specific mutations, insertion/deletions (indels), amplification/deletions, and genes fusions are indicated by colored circles for hematological malignant neoplasms and solid tumors. Only sequencing findings with biological significance are included. See the caption to Figure 3 for the types included in each neoplasm/tumor category and for the color key.](jamanetwopen-2-e192906-g004){#zoi190129f4}

Clinical Action Taken and Outcomes {#H2-7-ZOI190129}
----------------------------------

The clinical implications of these potentially actionable alterations for treatment decisions and/or outcomes were discussed and recorded following the MMTB review and recommendations. Actions were taken for 22 (41%) of 54 patients in all 4 categories ([Figure 1](#zoi190129f1){ref-type="fig"}). A summary of the action taken is given in the [Box](#zoi190129b1){ref-type="boxed-text"}, and representative examples are discussed here.

Disease-specific alterations were useful for targeted therapies as for patient 50,^[@zoi190129r29]^ who had a pilocytic astrocytoma diagnosis and who received a targeted treatment with a MEK inhibitor (trametinib dimethyl sulfoxide) according to the molecular profiling analysis, which uncovered a mutation in *NF1* (N1465S; 4763), a negative regulator of the Ras signal transduction pathway. Patient 50 remained clinically stable, and the last radiologic evaluation after 8 months of treatment showed a decrease in size and enhancing of the primary mass.

Patient 19 underwent a risk stratification change based on the *PAX5* (5079)-*JAK2* (3717) fusion identified by transcriptome analysis. This rearrangement is reported in Ph-like acute lymphoblastic leukemia subtype, a particularly aggressive subtype.^[@zoi190129r30]^ The molecular profiling has changed the diagnosis for patient 73, who initially received a Ewing-like sarcoma diagnosis on the basis of histologic appearance and immunohistochemistry, but the *EWSR1* (2130) and *FUS* (2521)--derived fusions were not detected by fluorescence in situ hybridization analysis. Transcriptome analysis revealed a *BRD4* (23476)-*NUTM1* (256646) fusion, which is exclusively reported in the very aggressive NUT (nuclear protein of the testis)--midline carcinoma, and therefore the diagnosis was changed consequently.

Several alterations were used for MRD monitoring. We identified the expression of at least 1 fusion gene in 12 patients with leukemia. In 9 cases, the expressed gene fusions were not detected in the clinical setting on the basis of targeted reverse transcriptase PCR, standard fluorescence in situ hybridization, or cytogenetic analysis. We developed reverse transcriptase PCR--based assays for 4 of these fusion genes (*PICALM* \[8301\]*-MLLT10* \[8028\], *NUP98* \[4928\]-*KDM5A* \[5927\], *PAX5-JAK2*, *DDX5* \[1655\]-*KLF2* \[10365\]) to allow MRD follow up for these patients. One of the patients died before discussing the results. The TRICEPS study analysis revealed, among others, the presence of the *KMT2E* (55904)-*ASNS* (440) fusion in conjunction with a cryptic t(10;11)(p13;q21) that was missed by conventional cytogenetics within the tumoral material in both patient 22 and patient 2.^[@zoi190129r14],[@zoi190129r16]^ These findings would have changed the stratification from the diagnosis, and patients would have been treated on a higher-risk arm (very high risk).

Discussion {#H1-4-ZOI190129}
==========

The TRICEPS study started as a feasibility study at a single institution to build a precision medicine program that integrates genomic data into clinical decision making. It was designed as a multimodal assay (WES and RNA sequencing) to reliably identify clinically relevant information derived from genomic profiling (SNV, indels, CNAs, gene fusions, and TMB) to guide personalized patient management. It was a comprehensive molecular profiling program, compared with similar ongoing studies (eTable 3 in the [Supplement](#note-ZOI190129-1-s){ref-type="supplementary-material"}). Patients enrolled in the TRICEPS study had advanced or metastatic cancer that was refractory to standard therapy, had relapsed after standard therapy, or had cancer for which no standard therapy was available. All eligible patients were recruited without regard to the probability of success. This cohort of consecutive patients provided a realistic insight into the distribution of patients with hard-to-treat cancers who could gain an advantage from molecular profiling in a clinical setting.

The present study showed that the molecular profiling (RNA libraries, sequencing, and bioinformatics analysis) of 62 of the 84 enrolled patients could be completed in a clinically reasonable median (range) time frame of 24 (4-41) days. This time frame is comparable to the median turnaround times, ranging from 28 to 54 days, in other studies.^[@zoi190129r17],[@zoi190129r22]^ Differences in the techniques used for the molecular profiling (WES, gene panel, RNA sequencing) explain most of the observed discrepancy between studies. Screening failures occurred in 22 patients because the tumor content was less than 25% or sufficient material was lacking. In comparison, other studies required a tumor content of at least 40% based on histologic assessment.^[@zoi190129r22]^ By integrating both WES and RNA sequencing, we identified potentially actionable alterations in 87% of the patients analyzed. Most of these mutations had not been detected by molecular testing as part of routine clinical care. These mutations in 62 patients were drug-targetable alterations, alterations that modify diagnosis or risk stratification, or alterations with a potential for disease monitoring; these findings are comparable with those in similar studies (eTable 3 in the [Supplement](#note-ZOI190129-1-s){ref-type="supplementary-material"}).

In addition to detecting SNVs and indels, WES enabled the identification of additional genomic events, including CNAs and TMB status, which may provide patients with treatment options that would have otherwise been missed. The TMB is a potential biomarker to evaluate response to immunotherapy.^[@zoi190129r31],[@zoi190129r32]^ As expected, we observed that the overall mutational burden in children and adolescents with cancer was lower than in adults with cancers.^[@zoi190129r33],[@zoi190129r34]^ The reported median TMB at age 10 years is 1.67 mutations/Mb (megabase),^[@zoi190129r34]^ but some tumors had a mutational burden above the mean (2-8 mutations/Mb) and could be referred to as pediatric highly mutated.^[@zoi190129r25]^ Whether these highly mutated pediatric tumors are candidates for immunotherapy remains to be investigated.

The inclusion of RNA sequencing provided valuable insights, particularly in leukemias and sarcomas, by detecting expressed fusion genes leading to new diagnoses, novel gene fusions, and new treatment options. Of the 57 cases in which RNA sequencing was performed, expressed fusions were detected in 40%, which led to the identification of 25 potentially actionable alterations. In this regard, patient tumors expressing oncogenic fusion proteins tended to be particularly sensitive to targeted inhibition of the fusion protein. One of the best examples is the treatment of leukemia with agents that affect Bcr-Abl kinase activity.^[@zoi190129r35],[@zoi190129r36]^ These RNA sequencing discoveries alone accounted for approximately 18% of the potentially actionable findings in this study, illustrating the added value of transcriptome analysis. The use of RNA sequencing to identify actionable expressed gene fusions has also been demonstrated in the INFORM^[@zoi190129r22]^ and the PEDS-MIONCOSEQ^[@zoi190129r17]^ studies.

We identified recurrent mutations in genes or related pathways, including tyrosine kinases, *JAK-STAT* gene, AKT/mTor pathway, MAPK pathway, and tumor suppressors (*TP53* and *CDKN2A*), that could be targeted by approved drugs. The MMTB identified 47 patients that could receive targeted therapy, 9 (19%) of whom were treated with the proposed alternative therapy. This percentage is similar to those reported by other studies, ranging from 3% to 19%.^[@zoi190129r17],[@zoi190129r19],[@zoi190129r22]^ The main barriers to the administration of targeted therapy in these patients included results that were available too late in the clinical course, limited drug access (regulatory and cost issues), and lack of an available clinical trial. In addition, we identified alterations, including novel alterations of previously unknown significance that have now been further characterized.^[@zoi190129r14],[@zoi190129r16]^

The yield of detection of potentially actionable alterations achieved in the TRICEPS study is in the upper range (87%) as compared with similar studies (eTable 3 in the [Supplement](#note-ZOI190129-1-s){ref-type="supplementary-material"}). The integration of WES-based methods to detect CNAs and RNA sequencing to identify fusion genes has increased the yield of potentially actionable alteration detection. The number of potentially actionable alterations identified may possibly have been overestimated, or other studies might have missed actionable mutations. This discrepancy could be partly explained by the lack of a standard definition for an actionable alteration and the level of evidence needed to support it. For instance, several studies considered only druggable genomic alterations, whereas other studies, including the TRICEPS study, recognized that nondruggable alterations might also be actionable or clinically relevant (eg, impact diagnosis, prognosis, or risk stratification). Other reasons for this discrepancy may include different cohort sizes, variable inclusion criteria, and investigation of specific cancer subgroups. In addition, the molecular profiling design, bioinformatics pipelines, and data analyses varied between studies. For instance, some precision medicine trials (eTable 3 in the [Supplement](#note-ZOI190129-1-s){ref-type="supplementary-material"}) were focused on specific cancer subtypes (eg, non--central nervous system solid tumors) and had limited genomic investigations (eg, gene panel).

Up to 10% of pediatric patients with cancer are estimated to carry an underlying hereditary cancer predisposition gene,^[@zoi190129r37]^ making the discovery of clinically relevant germline variants^[@zoi190129r38]^ inevitable during NGS analysis using germline SNVs to distinguish cancer-specific somatic mutations from constitutional variants. In the TRICEPS study, we detected pathogenic or likely pathogenic germline variants in 8 patients (13%), and this information was reported to the referring clinician. Patients and their families were then offered a referral to the medical genetics division for genetic counseling. In the future, we plan to use the WES data from the normal genome to assess interindividual variability in drug-related genes involved in absorption, distribution, metabolism, and excretion, which will allow us to estimate an individual's drug response and toxicological profile.

A key to the success of the TRICEPS study was the role played by the MMTB, which discussed, critiqued, and deliberated on molecular profiles and their actionable potentials. The NGS data were synthesized into a report that focused on putative actionable alterations, related pathways, and therapeutic alternatives. This report provided information to be used at the treating physician's discretion. The molecular profiling data were not meant to be prescriptive, but rather they were intended to provide novel information to guide the management of individual patients with cancer. The MMTB not only discussed the actionable potential of the molecular findings but also shared clinical, regulatory, and ethical issues associated with the findings. These MMTB meetings also served as a platform to train the next generation of scientists, clinicians, and other health professionals in the field of genomics to better understand the application of NGS data in a tailored-treatment strategy. Because of major improvements in caring for children and adolescents with hard-to-treat cancer, studies such as the TRICEPS study will likely become more frequent. Thus, exploring the ethical issues associated with these studies is important. More than 90% of parents reported that taking part in the TRICEPS study was advantageous for several reasons, but mainly it gave their children "all their chances" and an opportunity to give back (ie, improve care for future patients).^[@zoi190129r39]^

Limitations {#H2-8-ZOI190129}
-----------

This study is limited by the small numbers included. In addition, the heterogeneous nature of the patients made drawing general statements difficult. Because the purpose of this study was not to follow up with the patients, assessing the long-term implications of the actions taken was not possible.

Conclusions {#H1-5-ZOI190129}
===========

The present study appeared to demonstrate the feasibility of a comprehensive and real-time molecular profiling to identify actionable alterations in nonselected hard-to-treat childhood and adolescent cancers. Despite the challenges associated with translating genomic cancer landscape discoveries into a clinical setting, the TRICEPS study has shown its value to therapeutic management, including treatment options and diagnoses that change patient outcome. By generating clinically actionable findings, the TRICEPS study is establishing processes for incorporating NGS into routine cancer care. The development of standardized definitions for clinical categorization of somatic mutations will be critical to conducting comparative analyses between different genomic testing platforms and patient populations.
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[^1]: Abbreviations: AML, acute myeloid leukemia; B-ALL, B-cell acute lymphoblastic leukemia; ETP-ALL, early T-cell precursor acute lymphoblastic leukemia; GVHD, graft-vs-host disease; LOH, loss of heterozygosity; MRD, minimal residual disease; NUT, nuclear protein of the testis; RT-PCR, reverse transcriptase polymerase chain reaction; T-ALL, T-cell acute lymphoblastic leukemia; VEGF, vascular endothelial growth factor.
